Published in Obesity and Diabetes Week, June 27th, 2005
The patent is directed to a crystalline polymorph of Tarceva (erlotinib), methods for treating various cancers, and processes for production of the crystalline polymorph.
The claims in the patent will extend exclusive protection of Tarceva until 2020. "The issuance of the polymorph patent extends our current intellectual property protection for Tarceva by approximately 5 years," stated Colin Goddard, PhD, chief executive officer of the company.
Goddard added, "With a strong launch underway and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.